Anika Therapeutics
ANIK
125 hedge funds and large institutions have $302M invested in Anika Therapeutics in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 50 increasing their positions, 30 reducing their positions, and 10 closing their positions.
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
67% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 30
6% more funds holding
Funds holding: 118 → 125 (+7)
0.85% less ownership
Funds ownership: 93.96% → 93.11% (-0.85%)
11% less capital invested
Capital invested by funds: $341M → $302M (-$39.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$5.26M |
| 2 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$4.45M |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$3.22M |
| 4 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
+$2.41M |
| 5 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$2.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
-$29.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.37M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$540K |
| 4 |
Squarepoint
New York
|
-$484K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$462K |
ANIK Hedge Fund Activity: Q2 2022 in Review
125 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2022, worth a combined $302M — down 11% from $341M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ANIK positions and 10 closed out — a net gain of 10 holders — while 50 added to existing stakes and 30 trimmed.
The largest buyer was Portolan Capital Management, opening a new position worth an estimated $5.26M. The largest seller was Kayne Anderson Rudnick Investment Management, cutting an estimated $29.1M.
- 125 institutional investors held Anika Therapeutics (ANIK) as of Q2 2022, up from 118 in Q1 2022.
- Funds reported $302M of Anika Therapeutics stock for Q2 2022, down 11% quarter-over-quarter.
- 20 funds opened new Anika Therapeutics positions in Q2 2022 and 10 closed out, a net change of +10 holders.
- The largest Anika Therapeutics buyer in Q2 2022 was Portolan Capital Management, an estimated $5.26M added.
- The largest Anika Therapeutics seller in Q2 2022 was Kayne Anderson Rudnick Investment Management, an estimated $29.1M sold.
Based on aggregated 13F filings for Q2 2022.